Key Developments: Lupin Ltd (LUPN.NS)
768.40INR
6:11am EDT
Rs-0.05 (-0.01%)
Rs803.60
Rs774.00
Rs778.95
Rs758.00
1,238,096
911,782
Rs811.00
Rs496.40
Latest Key Developments (Source: Significant Developments)
Lupin Ltd. Announces Executive Board Leadership Changes
Lupin Ltd. announced that the Board of Directors of the Company at its meeting held on May 08, 2013, has approved the elevation of Mrs. Vinita Gupta as Chief Executive Officer (CEO) and Mr. Nilesh Gupta as Managing Director, effective September 1, 2013. Full Article
Lupin Ltd. Recommends Dividend
Lupin Ltd. announced that the Board of Directors of the Company at its meeting held on May 08, 2013, has recommended dividend at 200% i.e. INR4 per equity shares of the face value of INR2 each for the year ended March 31, 2013. Full Article
Lupin Ltd's Subsidiary Receives FDA Approval For Oral Contraceptive Pirmella 7/7/7 and Pirmella 1/35 Tablets
Lupin Ltd announced that its subsidiary Lupin Pharmaceuticals Inc. (collectively Lupin) has received final approval for its Pirmella 7/7/7 (Norethindrone and Ethinyl Estradiol Tablets USP, 0.5 mg/0.035 mg, 0.75 mg/0.035 mg and 1mg/0.035 mg) and Pirmella 1/35 Tablets (Norethindrone and Ethinyl Estradiol Tablets USP, 1 mg/0.035 mg) from the United States Food and Drugs Administration (US FDA) to market a generic version of Janssen Pharmaceuticals, Inc.’s Ortho Novum 7/7/7 Tablets and Ortho Novum 1/35 tablets. Lupin would commence shipping the product shortly. Full Article
Lupin Ltd Announces Allotment Of Equity Shares
Lupin Ltd announced that the Allotment Committee of Directors at its meeting held on April 23, 2013, has allotted 107,609 fully paid up equity shares of INR2 each. These shares have been allotted upon exercising of options. Full Article
US Court Finds Bayer AG’s Yaz Contraceptive Patent Claims Invalid; Actavis Inc, Drug Unit of Novartis AG And Lupin Ltd Involved in Rulling-Reuters
Reuters reported that a federal appeals court has ruled against Bayer AG, reversing a ruling by a lower court and finding that parts of a patent for the Company’s Yaz oral contraceptive were invalid. The United States Court of Appeals for the Federal Circuit ruled on April 16, 2013 that a district court in Nevada had erred in finding two claims of a patent for the contraceptive to be not invalid. It reversed the ruling. The generic companies involved in the ruling, Watson Pharmaceuticals, which now goes by the name Actavis Inc, Sandoz Inc - the generic drug unit of Novartis - and Lupin Ltd, had argued that the patent was invalid and had told the United States Food and Drug Administration that they planned to bring out generic versions of the contraceptive. The patent expires on June 30, 2014. Full Article
Lupin Ltd's Subsidiary Receives FDA Approval To Market Seasonique Tablets
Lupin Ltd announced that its subsidiary Lupin Pharmaceuticals Inc. (collectively Lupin) has received final approval for its Daysee Tablets (Levonorgestrel and Ethinyl Estradiol Tablets, USP, 0.15 mg/0.03 mg and Ethinyl Estradiol Tablets, USP, 0.01 mg) from the United States Food and Drugs Administration (US FDA) to market a generic version of Teva Branded Pharm’s Seasonique Tablets. Lupin has already commenced shipping the product. Lupin’sDaysee Tabletsisindicated for use by women to prevent pregnancy. Full Article
Lupin Ltd's Lupin Pharmaceuticals Inc Receives FDA Approval For New Drud Application For SUPRAX Oral Suspension 500 mg/5mL
Lupin Ltd announced that its subsidiary, Lupin Pharmaceuticals Inc. (collectively, Lupin) has received approval for SUPRAX (Cefixime) for Oral Suspension, 500 mg/5mL from the United States Food and Drugs Administration (FDA). Lupin expects to commence shipping the product in the near future. This new drug application provides for a new strength, 500mg/5mL, of SUPRAX (cefixime) for Oral Suspension for the treatment of otitis media, acute exacerbation of chronic bronchitis, uncomplicated urinary tract infections, uncomplicated gonorrhea (cervical/urethral) and pharyngitis/tonsillitis. Full Article
Lupin Ltd's Lupin Pharmaceuticals Inc Receives FDA Approval For Lorazepam Oral Concentrate USP, 2mg/mL
Lupin Ltd announced that its subsidiary Lupin Pharmaceuticals Inc. (collectively Lupin) has received final approval for its Lorazepam Oral Concentrate USP,2 mg/mL from the United States Food and Drugs Administration (USFDA) to market a generic version of Lorazepam Intensol, 2mg/mL, of Roxane Inc. Lupin’s Lorazepam Oral Concentrate USP, 2mg/mL is indicated for the management of anxiety disorders or for the short term relief of the symptoms of anxiety or anxiety associated with depressive symptoms. Full Article
Lupin Ltd To Launch Generic Drugs In US By March-End-Business Standard
Business Standard reported that Lupin Ltd, India's drugmaker, expects to launch three to four new generic drugs in key US market by March end, Group President Nilesh Gupta said on January 31, 2013. Full Article
Lupin Ltd's Subsidiary Receives FDA Approval for Generic Plan B Tablets, 0.75mg Tablets
Lupin Ltd announced that its subsidiary Lupin Pharmaceuticals Inc (collectively Lupin) has received final approval for its Levonorgestrel Tablets USP, 0.75 mg (Rx/OTC) from the United States Food and Drugs Administration (US FDA) to market a generic version of Teva Branded Pharmaceutical Products R&D, Inc.’s Plan B Tablets, 0.75 mg. Lupin’s Levonorgestrel Tablets Levonorgestrel 0.75mg tablets is a progestin-only emergency contraceptive, indicated for prevention of pregnancy following unprotected intercourse or a known or suspected contraceptive failure. Full Article
TABLE-India's Lupin Q4 net more than doubles
MUMBAI, May 8 - Three months ended March 31 (Versus the same period a year earlier, in billion rupees unless stated) Net Profit 4.08 vs 1.56 Net Sales 25.37 vs 18.83 Results are consolidated. NOTE: Lupin Ltd is a drugmaker. (Reporting by Kaustubh Kulkarni; Editing Anupama Dwivedi)
Earnings vs. 
Estimates
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
